期刊文献+

并发糖尿病的垂体生长激素腺瘤的围手术期治疗

下载PDF
导出
摘要 目的探讨并发糖尿病的垂体生长激素腺瘤的围手术期治疗方法和效果。方法对36例并发糖尿病的垂体生长激素腺瘤患者术前、术中、术后周密监测和调节血糖,把握手术时机,同时使用有效的抗生素预防感染,并采取措施避免心血管并发症的发生。结果术后2周血糖控制满意17例,需要口服降糖药控制血糖15例,仍需要皮下注射胰岛素4例。暂时性尿崩症3例,脑脊液漏2例,无颅内感染和死亡病例。结论并发糖尿病的垂体生长激素腺瘤的围手术期处理关键在于术前和术中血糖控制,而颅内感染和心血管并发症的预防亦不容忽视。
出处 《河北医科大学学报》 CAS 2012年第3期314-315,共2页 Journal of Hebei Medical University
  • 相关文献

参考文献8

  • 1钱荣立.关于糖尿病的新诊断标准与分型[J].中国糖尿病杂志,2000,8(1):5-6. 被引量:2314
  • 2RESMINI E, MINUTO F, COLAO A, et al. Secondary diabetes associated with principal endocrinopathies: the impact of new treatment modalities [ J ]. Acta Diabeto1,2009,46 ( 2 ) .. 85 - 95.
  • 3暴向阳,丁学华,卢亦成,胡国汉,骆纯,楼美清,张凤林,潘源.经蝶手术治疗垂体生长激素腺瘤的长期随访[J].中国临床神经外科杂志,2009,14(2):69-71. 被引量:5
  • 4凌伟华,惠国桢,李向东,吴思荣,徐峰,祁震宇.显微手术治疗肢端肥大症的长期随访分析[J].中华神经外科杂志,2008,24(1):39-41. 被引量:2
  • 5KASAYAMA S, OTSUKI M, TAKAGI M, et al. Impaired b - cell function in the presence of reduced insulin sensitivity determines glucose tolerance status in aeromegalic patients [ J ] Clin Endocrino1,2000,52 (5) : 549 - 555.
  • 6MICHAEL P, STAFFORD L, EDWARD R. Management of pituitary tumors : the clinician's practical guide [ M ]. 2nd ed. New Jersey : Humana Press ,2003 : 173 - 181.
  • 7KINOSHITA Y, FUJII H, TAKESHITA A, et al. Impaired glucose metabolism in Japanese patients with acromegaly is restored after successful pituitary surgery if pancreatic I beta t - cell function is preserved [ J ]. Eur J Endocfinal, 2011,164 (4) :467 - 473.
  • 8马驰原,史继新,王汉东,杭春华,成惠林,潘云曦,谢韡,孙康建,樊友武,李杰,李劲松.并发心血管病变的肢端肥大症的围手术期治疗[J].中华外科杂志,2005,43(17):1157-1157. 被引量:1

二级参考文献17

  • 1毛志钢,王海军,何东升,徐伟光,冯雷.影响垂体生长激素腺瘤经蝶手术疗效的因素分析[J].中国微侵袭神经外科杂志,2006,11(4):151-153. 被引量:7
  • 2Orme SM, Mcnally R J, Cartwright RA, et al . Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group [J]. J Clin Endoerinol Metab, 1998,83(8): 2730-2734.
  • 3Cottier JP, Destrieux C, Brtmereu L, et al . Cavernous sinus invasion by pituitary adenomas: MR Imaging [J]. Radiology, 2000, 215(2): 463-469.
  • 4Clemmons DR, Chihara K, Freda PU, et al . Optimizing control of acromegaly: integrating a growth hormone receptor antagonist into the treatment algorithm [J]. J Clin Endocrinol Metab, 2003, 88:4759-4767.
  • 5Minniti G, Jaffrain-Rea ML, Esposito V, et al . Evolving criteria for post-operative biochemical remission of acromegaly: can we achieve a definitive cure? An audit of surgical results on a large series and a review of the literature [J]. Endocr Relat Cancer, 2003, 10(4): 611-619.
  • 6Beauregard C, Truong U, Hardy J, et oi . Long-term out- come and mortality after transsphenoidal adenomectomy for acromegaly [J]. Clin Endocrinol (Oxf), 2003, 58(1): 86-91.
  • 7Santoro A, Minniti G, Ruggeri A, et al. Biochemical remission and recurrence rate of secreting pituitary adenomas after transsphenoidal adenomectomy: long-term endocrinologic follow-up results [J]. Surg Neurol, 2007, 68(5): 513-518.
  • 8Bates AS, vant Hoff W, Jones JM, et al . Does treatment of acromegaly affect life expectancy [J]? Metabolism, 1995, 44(suppl 1):1-5.
  • 9Ludecke DK, Abe T. Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1 000 operations IJ]. Neuroendocrinology, 2006, 83(3- 4): 230-239.
  • 10Oshino S, Saitoh Y, Kasayama S, et al . Short-term preoperative octreotide treatment of GH-secreting pituitary adenoma: predictors of tumor shrinkage [J]. Endocr J, 2006, 53(1): 125-132.

共引文献2318

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部